Cetin Hekimoglu, MD
Internal Medicine · McMinnville, TNNPI 1568488708
Payments from drug & device makers
Across 112 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$527
- AstraZeneca$272
- Lilly USA, LLC$245
- GSK$124
- Radius Health, Inc.$103
- Amgen$63
- plus $505 from 17 others
What the payments were for
- Food & beverage$1,840100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $527 |
| AstraZeneca | 14 | $272 |
| Lilly USA, LLC | 16 | $245 |
| GSK | 7 | $124 |
| Radius Health, Inc. | 4 | $103 |
| Amgen | 4 | $63 |
| AbbVie | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Pfizer | 3 | $53 |
| Bayer | 2 | $44 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $34 |
| Qorumpartners | 1 | $30 |
| Abbott | 1 | $25 |
| Astellas Pharma US Inc | 1 | $22 |
| Boehringer Ingelheim | 1 | $18 |
| Novartis | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$1,840 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 381 | $430,570 |
| OzempicSemaglutide | 207 | $246,196 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 159 | $161,335 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 116 | $98,605 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 110 | $95,863 |
| RybelsusSemaglutide | 47 | $83,179 |
| JardianceEmpagliflozin | 71 | $80,521 |
| Xigduo XrDapaglifloz Propaned/Metformin | 95 | $76,316 |
| EliquisApixaban | 74 | $67,236 |
| FarxigaDapagliflozin Propanediol | 48 | $50,481 |
| XifaxanRifaximin | 12 | $37,662 |
| TymlosAbaloparatide | 14 | $36,919 |
| VraylarCariprazine Hcl | 20 | $35,521 |
| TradjentaLinagliptin | 25 | $31,012 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $29,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $245 | $430,570381 claims |
| Novo NordiskOzempic, Rybelsus | $527 | $329,375254 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Stiolto Respimat, Combivent Respimat | $18 | $262,022276 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $124 | $183,133194 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $272 | $155,566186 claims |
| PfizerEliquis, Nurtec Odt | $53 | $96,09392 claims |
| AbbVieVraylar, Ubrelvy, Linzess | $62 | $80,86565 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $13 | $37,66212 claims |
| Radius Health, Inc.Tymlos | $103 | $36,91914 claims |
| Johnson & JohnsonXarelto | $34 | $24,20617 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $59 | $20,13612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $37 | $16,83617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in McMinnville
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.